Pharmacologic strategies for combating the inflammatory response

Journal of Extra-Corporeal Technology

Volumn 39, Issue 4, 2007, Pages 291-295

  Landis, Clive ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

Anti inflammatory; Antifibrinolytics; Cardiac surgery

Indexed keywords

ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTIOXIDANT; APROTININ; COMPLEMENT INHIBITOR; FONDAPARINUX; KALLIKREIN; LEUKOCYTE ANTIBODY; PEXELIZUMAB; PLACEBO; THROMBIN RECEPTOR; THROMBIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; SERINE PROTEINASE INHIBITOR;

BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CELL ACTIVATION; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYSIS; HEART MUSCLE INJURY; HUMAN; IMMUNOCOMPETENT CELL; KIDNEY FAILURE; STROKE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE ACTIVATION; REVIEW; RISK FACTOR;

APROTININ; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; FIBRINOLYSIS; HUMANS; KALLIKREINS; RISK FACTORS; SERINE PROTEINASE INHIBITORS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 40949095354     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. Hsu LC. Biocompatibility in cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1997;11:376-82.
2. Soderstrom T, Hedner U, Arnljots B. Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury. J Vasc Surg. 2001;33:1072-9.
3. De Somer F, Van Belleghem Y, Caes F, et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2002;123:951-8.
4. McNeely TB, Griffith MJ. The anticoagulant mechanism of action of heparin in contact-activated plasma: inhibition of factor X activation. Blood. 1995;65:1226-31.
5. Spanier TB, Oz MC, Minanov OP, et al. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thorac Cardiovasc Surg. 1998;115:1179-88.
6. Shann KG, Likosky DS, Murkin JM, et al. An evidence-based review of the practice of cardiopulmonary bypass in adults: A focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response. J Thorac Cardiovasc Surg. 2006;132:283-90.
7. Landis RC. Why thrombin PAR1 receptors are important to the cardiac surgical patient. J Extra Corpor Technol. 2007;39: (in press).
8. Landis RC. Protease activated receptors: Clinical relevance to hemostasis and inflammation. Hematol Oncol Clin North Am. 2007;21:103-13.
9. Day JR, Taylor KM, Lidington EA, et al. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg. 2006;131:21-7.
10. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993;106:1-9.
11. Landis RC, Asimakopoulos G, Poullis M, Haskard DO, Taylor KM. The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg. 2001;72:2169-75.
12. Kamiya T, Katayama Y, Kashiwagi F, Terashi A. The role of bradykinin in mediating ischemic brain edema in rats. Stroke. 1993;24:571-5.
13. Gott JP, Cooper WA, Schmidt FE Jr, et al. Modifying risk for extracorporeal circulation: Trial of four antiinflammatory strategies. Ann Thorac Surg. 1998;66:747-53.
14. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004;128:442-8.
15. Smith PK, Datta SK, Muhlbaier LH, Samsa G, Nadel A, Lipscomb J. Cost analysis of aprotinin for coronary artery bypass patients: Analysis of the randomized trials. Ann Thorac Surg. 2004;77:635-42.
16. Clark WM, Madden KP, Rothlein R, Zivin JA. Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. Stroke. 1991;22:877-83.
17. Asimakopoulos G, Thompson R, Nourshargh S, et al. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg. 2000;120:361-9.
18. Asimakopoulos G, Lidington EA, Mason J, Haskard DO, Taylor KM, Landis RC. Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg. 2001;122:123-8.
19. Pruefer D, Makowski J, Dahm M, et al. Aprotinin inhibits leukocyteendothelial cell interactions after hemorrhage and reperfusion. Ann Thorac Surg. 2003;75:210-5.
20. Anttila V, Hagino I, Iwata Y, et al. Aprotinin improves cerebral protection: evidence from a survival porcine model. J Thorac Cardiovasc Surg. 2006;132:948-53.
21. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-65.
22. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA. 2007;297:471-9.
23. Aronson S, Fontes ML, Miao Y, Mangano DT. Risk index for perioperative renal dysfunction/failure: Critical dependence on pulse pressure hypertension. Circulation. 2007;115:733-42.
24. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2001;17:CD001886.
25. Brown JR, Birkmeyer NJ, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation. 2007;115:2801-13.
26. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary artery bypass grafting: Effect on postoperative renal function. Ann Thorac Surg. 1995;59:132-6.
27. Kincaid EH, Ashburn DA, Hoyle JR, Reichert MG, Hammon JW, Kon ND. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery? Ann Thorac Surg. 2005;80:1388-93.
28. Bridges CR. Valid comparisons of antifibrinolytic agents used in cardiac surgery. Circulation. 2007;115:2790-2.
29. van der Linden J, Lindvall G, Sartipy U. Aprotinin decreases post-operative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial. Circulation. 2005;112(Suppl 9):I276-80.
30. Verrier ED, Shernan SK, Taylor KM, et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: A randomized trial. JAMA. 2004;291:2319-27.
31. Fitch JCK, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation. 1999;100:2499-506.
32. Shernan SK, Fitch JCK, Nussmeier NA, et al. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg. 2004;77:942-9.
33. Eppinger MJ, Deeb GM, Bolling SF, Ward PA. Mediators of ischemia-reperfusion injury of rat lung. Am J Pathol. 1997;150:1773-84.
34. Seekamp A, Mulligan MS, Till GO, et al. Role of beta 2 integrins and ICAM-1 in lung injury following ischemia-reperfusion of rat hind limbs. Am J Pathol. 1993;143:464-72.
35. Kaneider NC, Agarwal A, Leger AJ, Kuliopulos A. Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med. 2005;11:661-5.
36. Kaneider NC, Leger AJ, Kuliopulos A. Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions. FEBS J. 2006;273:4416-24.
37. Vuorte J, Lindsberg PJ, Kaste M, et al. Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood. J Immunol. 1999;162:2353-7.
38. Furuya K, Takeda H, Azhar S, et al. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: A bedside-to-bench study. Stroke. 2001;32:2665-74.
39. Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: Results of the Enlimomab Acute Stroke Trial. Neurology. 2001;57:1428-34.
40. Frank RD, Holscher T, Schabbauer G, et al. A non-anticoagulant synthetic pentasacharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury. Thromb Haemost. 2006;96:802-6.
41. Gott JP. Leukodepletion and aprotinin improve clinical outcome after extracorporeal circulation. Perfusion. 2001;16(Suppl 1):5-9.
42. Siderys H, Herod GT, Halbrook H, et al. A comparison of membrane and bubble oxygenation as used in cardiopulmonary bypass in patients. The importance of pericardial blood as a source of hemolysis. J Thorac Cardiovasc Surg. 1975;69:708-12.
43. Minneci PC, Deans KJ, Zhi H, et al. Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest. 2005;115:3409-17.
44. Fagoonee S, Gburek J, Hirsch E, et al. Plasma protein haptoglobin modulates renal iron loading. Am J Pathol. 2005;166:973-83.
45. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res. 2005;96:435-41.
46. Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care. 2003;26:2628-31.
47. Roguin A, Ribichini F, Ferrero V, et al. Haptoglobin phenotype and the risk of restenosis after coronary artery stent implantation. Am J Cardiol. 2002;89:806-10.
48. Levy AP, Roguin A, Hochberg I, et al. Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med. 2000;343:969-70.
49. Christen S, Finckh B, Lykkesfeldt J, et al. Oxidative stress precedes peak systemic inflammatory response in pediatric patients undergoing cardiopulmonary bypass operation. Free Radic Biol Med. 2005;38:1323-32.
50. McBride WT, Armstrong MA, Crockard AD, McMurray TJ, Rea JM. Cytokine balance and immunosuppressive changes at cardiac surgery: contrasting response between patients and isolated CPB circuits. Br J Anaesth. 1995;75:724-33.
51. Jegger D, Horisberger J, Jachertz M, et al. A novel device for reducing hemolysis provoked by cardiotomy suction during open heart cardiopulmonary bypass surgery: A randomized prospective study. Artif Organs. 2007;31:23-30.
52. Hammon JW, Stump DA, Butterworth JF, et al. Single crossclamp improves 6-month cognitive outcome in high-risk coronary bypass patients: The effect of reduced aortic manipulation. J Thorac Cardiovasc Surg. 2006;131:114-21.
53. Tanaka K, Kanamori Y, Sato T, et al. Administration of haptoglobin during cardiopulmonary bypass surgery. ASAIO Trans. 1991;37:M482-3.